|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?显示文摘Nonalcoholic fatty liver disease(NAFLD) is the most common liver disease worldwide, affecting approximately one third of the Western world. It consists of a wide spectrum of liver disorders, ranging from fatty liver to nonalcoholic steatohepatitis(NASH), which consists of steatosis, ballooning injury and inflammation. Despite an alarming growth in the statistics surrounding NAFLD, there are as yet no effective therapies for its treatment. Innate immune signaling has been thought to play a significant role in initiating and augmenting hepatic inflammation, contributing to the transition from nonalcoholic fatty liver to NASH. An immune response is triggered by countless signals called damage-associated molecular patterns(DAMPs) elicited by lipid-laden and damaged hepatocytes, which are recognized by pattern recognition receptors(PRRs) on hepatic immune cells to initiate inflammatory signaling. In this editorial, in addition to summarizing innate immune signaling in NAFLD and discussing potential therapies that target innate immune pathways, we have described a recent study that demonstrated that mitochondrial DNA serves as a DAMP activating a hepatic PRR, TLR9, in mice and in the plasma of NASH patients. In addition to identifying a new ligand for TLR9 during NASH progression, the study shows that blocking TLR9 reverses NASH, paving the way for the development of future NASH therapy. | Priya Handa Akhila Vemulakonda Kris V Kowdley Misael Uribe Nahum Méndez-Sánchez | 2016 | World Journal of Gastroenterology2016，22，31： | 3 |
| 2 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 3 | Functional interaction of β-catenin with the transcription factor LEF-1显示文摘 | Behrens J von Kries JP Kuhl M | 1996 | Nature1996，382，6592： | 1 |
| 4 | Matrix-independent survival of human keratinocytes through an EGF receptor/ MAP kinase-dependent pathway 显示文摘 | Jost M Huggett TM Kri C | 2001 | Mol Biol Cell2001，12，： | 1 |
| 5 | Gefitinib ('Iressa',ZD1839) monotherapy for pretreated advanced non-smallcell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone显示文摘 | Bailey R Kris M Wolf M | 2003 | Lung Cancer2003，41，2： | 1 |
| 6 | Iden- tification of driver mutation in specimens from 1000 pa- tients with lung adenocarcinoma: The NCI' s Lung Cancer Mutation Consortium ( LCMC ) AbstractCRA7506 显示文摘 | Kris M G Johnson B E Kwiatkowski D J | 2011 | J Clin 0ncol2011，29，20： | 1 |
| 7 | Dietary fatty acids, hemostasis, and cardiovascular disease risk 显示文摘 | LEFEVER M KRIS - ETJERTPM P M | 2004 | J Am Diet Assoc2004，104，： | 1 |
| 8 | Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial显示文摘 | Kris M Natale R Herbst R | 2003 | JAMA2003，290，： | 1 |
| 9 | Excessive crying beyond 3 months may herald other features of multiple regulatory problems显示文摘 | Von Kries R Kalies H Papousek M | 2006 | Arch Pediatr Adolesc Med2006，160，： | 1 |
| 10 | Quality of life assessment in individuals with lung cancer:testing the Lung Cancer Symptom Scale (LESS) 显示文摘 | Hollen P J Gralla R J Kris M G | 1993 | European Journal of Cancer1993，29，： | 1 |
| 11 | Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib('Iressa',ZD1839)monotherapy for pretreated advanced non-small-cell lung cancer:IDEAL 1 and 2显示文摘 | Bailey LR Kris M Wolf M | 2003 | Proc Am Assoc Cancer Res2003，44，： | 1 |
| 12 | Novel membrane technology for food and water monitoring 显示文摘 | Kris J Senecal Jason Soares C M Mello | 2004 | Monitoring Food Safety Agriculture and Plant Health2004，5271，： | 1 |
| 13 | Recommendations for the Use of Antiemetics:Evidence-Based,Clinical Practice Guidelines,American Society of Clinical Oncology显示文摘 | Gralla R J Osoba D Kris M G | 1999 | J Clin Oncol1999，17，9： | 1 |
| 14 | Frequency and distinc- tive spectrum of KRAS mutations in never smokers, with lung ade- nocarcinoma显示文摘 | Riely G J Kris M G Rosenbanm D | 2008 | Clin Cancer Res2008，14，18： | 1 |
| 15 | High - monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations 显示文摘 | KRIS - ETHERTON P M PEARSON T A WAN Y | 1999 | Am J Clin Nutr1999，70，6： | 1 |
| 16 | Functional interaction of β-catenin with the transcription factor LEF-1 显示文摘 | Behrens J von Kries J P Kunl M | 1996 | Nature1996，382，： | 1 |
| 17 | Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyorsinekinase, in symptomatic patients with non-small cell lung cancer: randomized tfial 显示文摘 | Kris M G Natale R B Herbst R S | 2003 | JAMA2003，290，16： | 1 |
| 18 | Lung cancer in US women: a contemporary epidemic 显示文摘 | PATEL J D BACH P B KRIS M G | 2004 | J Am Med Assoc2004，291，14： | 1 |
| 19 | Efficacy of Gefinitib, an inhibitor of the epidermal growth factor tyrosine kinase,in symptomatic patients with non-smalll cell lung cancer 显示文摘 | Kris M G Natale R S Herbst R S | 2003 | JAMA2003，290，16： | 1 |
| 20 | Modifying actions of solvent extracts from fruit and vegetable residues on 2-amino-3-methylimidazo quinolin and 2-amiono-3,4-dimethylimidazo auinoxaline induced mutagenesis in Salmonella typhimurium TA98显示文摘 | Edenharder R Leopold C Kries M | 1995 | Mutat Res1995，341，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员